US Broker Ratings

SI-BONE, Inc. (SIBN): Investor Outlook on a High-Potential Medical Device Innovator with 27.77% Upside

SI-BONE, Inc. (NASDAQ: SIBN) stands out as a promising player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $845.26 million, this U.S.-based company..

Cronos Group Inc. (CRON) Stock Analysis: Navigating a Challenging Yet Promising Market Landscape

Cronos Group Inc. (NASDAQ: CRON), a key player in the global cannabinoid market, continues to capture the attention of investors with its unique position in the healthcare sector. Despite a..

CareDx, Inc. (CDNA) Stock Analysis: Unveiling a 25.40% Potential Upside in the Healthcare Diagnostics Sector

CareDx, Inc. (NASDAQ: CDNA), a prominent player in the healthcare sector specializing in diagnostic solutions for transplant patients, has recently caught the attention of investors with a potential upside of..

Iovance Biotherapeutics (IOVA) Stock Analysis: Unpacking the 238% Potential Upside

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a notable player in the healthcare sector, specifically in biotechnology, has captured the attention of investors with its significant potential upside. As a commercial-stage biopharmaceutical..

Xencor, Inc. (XNCR)

⚠️ No article content returned.

..

ArriVent BioPharma, Inc. (AVBP) Investor Outlook: Assessing a 72.23% Potential Upside in Biotech Innovation

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing attention in the biotech sector with its innovative approach to tackling unmet medical needs in cancer treatment. With a market capitalization of $951.54..

Intellia Therapeutics, Inc. (NTLA) Growth Potential: Why Analysts See a 163% Upside

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is capturing attention in the biotechnology sector with its innovative approach to gene editing. Headquartered in Cambridge, Massachusetts, Intellia is a clinical-stage company that specializes..

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Soaring Prospects with 119.86% Potential Upside

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is attracting significant interest from investors, particularly given its compelling potential upside of 119.86%. This biopharmaceutical company, headquartered in Cambridge, Massachusetts, specializes in developing innovative..

Ardelyx, Inc. (ARDX) Stock Analysis: Exploring a 95% Potential Upside with Innovative Biotech Solutions

Ardelyx, Inc. (NASDAQ: ARDX) has emerged as a notable player in the biotechnology sector, drawing investor attention with its promising drug portfolio and significant potential upside. With a current market..

CeriBell, Inc. (CBLL) Stock Analysis: Navigating a 46% Potential Upside in the Medical Device Sector

CeriBell, Inc. (NASDAQ: CBLL), a cutting-edge player in the healthcare sector, is capturing attention with its innovative medical devices and a notable potential upside of 46.15%. As a company dedicated..

CorMedix Inc. (CRMD): Investor Outlook with a 96.89% Potential Upside

CorMedix Inc. (NASDAQ: CRMD), a promising player in the biotechnology sector, is capturing investor attention with its impressive growth metrics and significant potential upside. As a biopharmaceutical company focused on..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Exploring a Potential 11.66% Upside Amid Growing Revenue

Fulgent Genetics, Inc. (FLGT), a prominent player in the healthcare sector’s diagnostics and research industry, is drawing attention from investors with a notable potential upside of 11.66%. Nestled in the..

Embecta Corp. (EMBC): Investor Outlook on a 32.59% Potential Upside in Healthcare Innovation

Embecta Corp. (NASDAQ: EMBC) stands at the intersection of innovation and healthcare, offering compelling opportunities for investors focused on the medical instruments and supplies sector. With a market capitalization of..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A 129% Upside Potential That Investors Can’t Ignore

Niagen Bioscience, Inc. (NASDAQ: NAGE), a dynamic player in the biotechnology sector, is grabbing the attention of investors with its remarkable potential upside and robust growth metrics. The company, headquartered..

Gyre Therapeutics, Inc. (GYRE) Stock Analysis: Promising 129% Upside Potential with Robust Pipeline

Gyre Therapeutics, Inc. (NASDAQ: GYRE), a key player in the biotechnology sector, is generating notable interest among investors due to its promising drug pipeline and substantial potential for stock price..

Nurix Therapeutics, Inc. (NRIX): Analyst Ratings Suggest 58% Upside Potential in Biotech Sector

Nurix Therapeutics, Inc. (NRIX) is making waves in the biotechnology sector, with promising developments in its clinical-stage pipeline and strong analyst support suggesting a notable upside for investors. This San..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Promising 76.93% Upside in the Biotech Arena

Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company, is making waves in the healthcare sector with its ambitious focus on innovative treatments for inflammatory bowel disease (IBD). With a market..

Rocket Pharmaceuticals, Inc. (RCKT) Investor Outlook: Unpacking a 141.78% Potential Upside

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is gaining attention in the biotechnology sector, not only for its focus on developing gene therapies for rare diseases but also for its eye-catching potential..

Xeris Biopharma Holdings, Inc. (XERS): Investor Outlook on a Promising 60% Upside Potential

For investors seeking exposure to the dynamic world of biotechnology, Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) presents a compelling opportunity. With a market capitalization of $1.19 billion, this Chicago-based firm..

Nuvation Bio Inc. (NUVB) Stock Analysis: Revenue Growth Soars with 27.97% Potential Upside

Nuvation Bio Inc. (NASDAQ: NUVB) has recently captured the attention of investors, thanks to its impressive revenue growth and a significant potential upside. With a market capitalization of $2.75 billion,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds